 Hi, how's everybody doing today? I'm your host Rich here on behalf of RichTV Live with our very special guest. It is the CEO of Numinous Wellness, Payton NightQuest. How you doing today, Payton? I'm doing well. Thanks. Thanks for having me. Thank you for joining us. Very excited to have you on the show. Our community is very excited about Numinous Wellness. Many of us are heavily invested in the company and we love what you guys are doing. Numinous Wellness is a mental health and wellness company creating an ecosystem of solutions centered around safe, evidence-based, accessible psychedelic assisted psychotherapy. Can you tell us a bit more about what you do? Yeah, so really the company is split up into two verticals really. Our Numinous Bioscience Division, which is our Health Canada license lab and production facility that has some very extensive licensing, which we can get into later, but really focusing more on the drug itself and all that sort of circulates around that. And then our Numinous Health Division is our clinical network. We have multiple locations across the country in Canada and looking to expand that also south of the border and internationally. And then Numinous R&D is really our division that sort of is the jet fuel that feeds both of those divisions where we do all of our protocol development, clinic SOP development as well as research on these different therapies and medications. Great. And what fueled the company's decision to focus on mental illness? Yeah, really personally led. I had suffered with some severe chronic health issues as well as sort of a conjunction with mental health things that I was struggling with as well and actually got led to psychedelic assisted psychotherapy to try and save my own life a number of years ago and did so. And at the time there was really no corporate interest in the psychedelic therapy space, but a ton of amazing research being done by a lot of leading academic research institutions, which led me to look into this more and more and recognize that there was just a huge gap that was needed in terms of infrastructure to be able to actually house all of this amazing research that was being done and build the infrastructure needed to be able to support that and provide access for people who need it. What differentiates Numinous Wellness from other companies in the space? I see there's an explosion of new companies. What makes you guys unique? Yeah, I think we encourage a lot of the obviously the growth that's happened in the space is encouraging and very much needed. For us, we believe we're in a leadership position, whether it's our amount of expertise that we have in the space, both of our business lines have been operating, we have a clinic network that's been operating now for over 10 years. The lab that we do have has been operating for over 10 years as well, so a huge amount of experience in the space. The Health Canada licensing that I mentioned is really, we believe industry leading in terms of the amount of enablement that Health Canada has allowed us to be able to do in the space and then really getting back to that evidence-based approach that we've taken and that includes partnerships with leading research institutions like MAPS, for example, who I'm sure a lot of people who are watching this probably know of, just huge enablement through that partnership to be able to be an industry leader in that particular realm of MDMA-assisted psychotherapy for post-traumatic stress disorder. Now the government of Canada is beginning to change its view on psychedelics, which you touched on. Can you talk a little bit about that and what that means for the company? Yeah, I think you really saw a huge shift in Canada in the summer of last year with a lot of the Section 56 exemptions that started to be enabled with people using psilocybin for end-of-life anxiety. That ball has really just continued to roll. We've been doing some work with Health Canada around the special access drug program, which is a program in Canada that enables Canadians to be able to access drugs or therapies before they finish going through the clinical trial process. Psychedelics previously had been exempt from being able to be included in the special access drug program, and our team actually provided a briefing note to Health Canada in about November of last year stating the request to have psychedelics be able to be applied for the special access drug program. On the backs of that briefing note, Health Canada actually announced in December of last year their intentions to change the special access drug program to include MDMA and psilocybin. So Health Canada has really taken a leadership position around changing drug policy rules to be able to include psychedelic-assisted psychotherapy. Now there's also been a first-ever psychedelics ETF and it just launched in the last little while and Numinous has been included in the lineup. I think it's one of the bigger holdings. What does this mean for the company and the psychedelic space? Yeah, I think it just continues to validate the psychedelic space. We're very grateful to be able to be involved and to be, as you mentioned, one of the heavier weighted companies in the ETF. It's validating for shareholders. We were one of the first public companies in the psychedelic space and I think still the only public company on the TSX in the psychedelic space as well. The more comfort that shareholders can have, the more exposure that shareholders can have to be able to, as you mentioned, I see it feels like a new company a day that's going public in the space and I think to be able to create discernment for shareholders, which companies are really there to create value versus companies that might be there because this industry is getting a lot of attention and there is a lot of capital being thrown at the space. I think obviously learning a little bit from some of the lessons in the cannabis space, I think investors want to make sure that they're being very educated in terms of what is actually happening and what is moving the needle in the psychedelic space as it is so new still. But also for people looking for this therapy, I think the thing not to be forgotten about is these are therapies that are needed now more than ever. Mental health continues to be a growing issue in our society today, if not probably one of the leading issues in society today and I think the more ores that are paddling all in the same direction here, especially in the early going are extremely important. I think there's been a huge shift growing up. You didn't hear about mental, I'm 43 growing up. I didn't hear about mental illness. Now it's all I hear about. So this is not a want. This is a need and it's a problem that is a growing problem like you said. Now you guys have also launched clinics in Vancouver and Montreal. Can you explain what's going on there? Yeah, so our Vancouver clinic is a clinic that we acquired a couple of years ago when we were still private. It was a clinic that had been operating for five years and really, sort of an integrative mental health clinic. So doing a lot of, as we just mentioned, mental health focus therapies and treatments for people. Ketamine obviously is something that's been getting a lot of attention lately. So we do plan on initiating where the clinic is currently under renovations to be able to hold the MDMA and psilocybin work that we intend on doing this summer. And as well, starting to initiate some of the ketamine work for depression and mood disorder. And then in Montreal, we acquired a group called Mindspace, which is really a Canada leading organization around mental health and mindfulness practices. And they have built a really robust training platform, as well as a ketamine assisted psychotherapy program as well. And as I mentioned, they come with over 10 years of experience building that brand and have multiple locations in Montreal. As well as, you know, with what's gone on with COVID, they've built an extremely strong virtual services platform as well. Very good. Very good. Now you mentioned a little bit about maps. So you've also just recently signed a collaboration agreement with maps. Can you tell us a little bit more about that deal? Yeah, I think the thing to share there more than anything is, that's really, it's not a one page or news release kind of collaboration. That was a collaboration that had taken the better part of a couple years to really develop the amount of paperwork that's on the back end of that collaboration is extremely robust. You know, for us, we see the biggest bottleneck around psychedelic assisted psychotherapy is the trained practitioners to be able to actually carry out the treatment for people. You know, it's great to go and open 100 clinics, but if you don't have the people that can actually do the work, you're just tacking on a lot of burn rate and wasting a lot of resources. So maps really is the reason why psychedelics are where they are today in North America, the amount of work that they've been doing since 1986 with MDMA for post-traumatic stress disorder, really paved the way for a lot of other psychedelic research. And they've now got MDMA in FDA phase three clinical trials and MDMA for post-traumatic stress disorder probably will be the first psychedelic to complete the FDA clinical trial process and be legal for people to access that therapy. So our partnership with them is extremely robust all the way through to the training of practitioners. We've recently trained a number of our staff to be trained by maps to be able to provide MDMA assisted psychotherapy. They've agreed to share their protocol with us. So we will be initiating an open label single arm clinical trial for MDMA for PTSD out of our Vancouver location this summer. So, you know, as I mentioned, very robust and it's actually maps. It's the first industry partnership that maps has has ever done. So we're very grateful to be able to to be in that category. That's great. Is there anything else investors should watch out for for new menace in the coming months? Any catalysts? You know, can't can't tip my hat too much, but we made a lot of representations last year. This year is really about growth for us. We've already built an extremely strong platform and infrastructure. So it's really about execution for us. And, you know, we've recently bolstered the balance sheet and filled the till with with quite a lot of capital as well. So very well resourced, very strong plan in place. And so I think over the next couple of months, you're going to see quite a lot of exciting growth in the company. And we're really looking forward to sharing it with everybody. That's great. Payton, we're going to have this shown to our community, which is in over 100 countries worldwide. Lots of investors are going to want to contact you potential partners. We've had other psychedelic companies on here that might want to do an LOI or a joint venture. Who knows? What's the best way for someone who's interested in contacting the company to reach you guys? Yeah, best thing to do is go on our website, newmenace.ca. We've got a few different portals, depending on what you're looking to engage with, whether that's partnership investment. So I encourage everybody to go through there. And we have a newsletter that we put out monthly that is a great way for people to keep up to date with what we're doing. So really suggest people subscribed to the newsletter. We don't hammer people's inboxes and we make sure that it's relevant and topical for people. So really encourage people to subscribe to that as well. Great. Well, thank you for joining us today. Payton, very excited about watching your company evolve and grow. I think you guys are doing great work. Like I said, this is not a want. In my opinion, this is a need. This is a direction that the whole world is going. And newmenace wellness happens to be one of the leaders. So you guys are doing great work. Now, anyone that's watching, remember Rich TV Live is strictly for education, entertainment purposes. Always consult a financial advisor before you invest in any companies that we discuss or talk about here in Rich TV Live. Chances are when you go and you speak to your financial advisor and they've done their due diligence on newmenace wellness, they're going to say, wow, would you get that pick? And you can say from Rich TV Live and they're going to say it's a really good pick. And I agree. I think the company has enormous upside. Like you said, well-capitalized and still very responsible with your share structure. If you guys liked the video, please smash the like button. Comment down below, share the video everywhere and subscribe. Hit the bell for notifications. So anytime we have any breaking news, you get access to it first. Thank you for joining us today. The CEO of newmenace wellness, Payton NightQuest. Thank you for joining us today, Payton. Thanks for having me. Really appreciate the support. Always a pleasure. Thank you guys for watching and have yourselves a nice day.